CMS’s voluntary bundled payment evaluation finds uneven results

The evaluation of models 2-4 of Medicare’s Bundled Payments for Care Improvement (BPCI) initiative highlighted mixed results on savings and quality in the first 15 months of the program.

Patrick Conway, MD, acting principal deputy administrator and chief medical officer for CMS, was optimistic about the results of the experience of participants through June 2015. In a blog post, he pointed to how “11 out of the 15 clinical episode groups analyzed showed potential savings to Medicare.”

“Early results are encouraging: orthopedic surgery bundles, in particular, have shown promising results on cost and quality in the first two years of the initiative,” Conway wrote. “These models keep the patient at the center of care delivery and focus on well-coordinated, high quality care.”

According to the evaluation, orthopedic surgery under Model 2 hospitals showed savings of $864 per episode while also improving 90-day post-discharge scores on mobility under surveys of beneficiaries.  

For cardiovascular episodes at Model 2 hospitals, Conway said no savings were shown but quality scores didn’t decline.

On the negative side, however, the evaluation said average payments for spinal surgery episodes increased $3,477 more than comparison providers, which the report said “warranted further investigation.”

Future evaluations may be more indicative of the effects on cost and quality, as sample sizes will be much larger with more participants joining the program in the past year. The report warned against “generalizing these results to other providers or the full range of clinical episodes.”

“The study reflects, at most, the first 15 months of experience of the earliest BPCI participants,” the evaluation said. “Because of limited sample sizes, we are not able to report on the experience of each combination of Model/participant type/ clinical episode group. Limited sample sizes, in particular, have affected our ability to understand the differential impact of BPCI across types of participants, health care delivery, and the Medicare program.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.